scienceMar 9, 202619:21failed
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
About this episode
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.
CME information and select publications here.
Get every episode summarized
Each time Hematologic Oncology Update publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Hematologic Oncology Update
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal S...
Hematologic Oncology Update
Mar 13, 20261:03:21failed
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Pre...
Hematologic Oncology Update
Mar 11, 202647:10completed
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH...
Hematologic Oncology Update
Mar 4, 202624:25pending
Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
Hematologic Oncology Update
Feb 18, 202657:58pending